News
CAMBRIDGE, MA, USA & SALISBURY, USA I July 07, 2025 I KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY ® ...
GENEVA, Switzerland I July 07, 2025 I Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced its ...
Research published in Science Advances indicates that CVXGA is a promising intranasal vaccine candidate that is safe, immunogenic and potentially effective ...
PARIS, France I July 07, 2025 I PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with ...
TOKYO, Japan I July 7, 2025 I Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter “Chugai”), and Gero PTE. LTD. (hereafter “Gero”), a Singapore-based ...
VIENNA, Austria / BERLIN, Germany I July 7, 2025 I HeartBeat.bio AG and biotx.ai GmbH today announced astrategic partnership to identify and validate ...
SHANGHAI, China I July 4, 2025 I Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing ...
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the ...
CINCINNATI, OH, USA I July 4, 2025 I During the COVID-19 pandemic, scientists learned that the critical path to infection started with the SARS-CoV-2 virus ...
BOSTON, MA, USA I July 4, 2025 I HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule ...
GUANGZHOU, China I July 2, 2025 I Bio-Thera Solutions, Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced ...
BOSTON, MA, USA I July 02, 2025 I Modella AI, a leader in artificial intelligence for life sciences, today announced a multi-year agreement with AstraZeneca. Under the agreement, Modella AI will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results